Steven Zelenkofske, DO, vice president of US Medical Affairs at AstraZeneca, talked with MD Magazine about the CVD-REAL study where researchers examined patients with type 2 diabetes taking the new class of diabetes drug, SGLT-2 inhibitors. Positive outcomes were reported with dapagliflozin, canagliflozin, and empagliflozin.
The CVD-REAL study examined 300,000 patients with type 2 diabetes from 6 different countries. The aim was to uncover the risk of heart failure hospitalizations and all-cause death in these patients, 87% of which didn’t have a history of cardiovascular disease.
Steven Zelenkofske, DO, vice president of US Medical Affairs at AstraZeneca, talked with MD Magazine about the real-world study at the 66th Scientific Session of the American College of Cardiology (ACC 2017) in Washington, District of Columbia.
The SGLT-2 inhibitors used in this study were dapagliflozin (Farxiga/AstraZeneca), canagliflozin (Invokana/Janssen), and empagliflozin (Jardiance/Eli Lilly and Company). These drugs reduced the rate of hospitalization for heart failure by 39% (hazard ratio (HR): 0.61; 95% confidence interval (CI) 0.51-0.73; P < 0.001) and all-cause mortality by 51% (HR: 0.49; 95% CI 0.41-0.57; P < 0.001). The overall reduction for hospitalization for heart failure and all-cause mortality was 46% (HR: 0.54; 95% CI 0.48-0.60; P < 0.001).
“The beauty of this study is that it’s very applicable to the decision-making that a practitioner has to make when they’re sitting front of a patient,” Zelenkofske said.